Tuberculosis

European Respiratory Review

Volumn 23, Issue 131, 2014, Pages 36-39

  Robert Horsburgh Jr , C ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BACTERIAL DNA; BCG VACCINE; BEDAQUILINE; DELAMANID; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PLACEBO; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

AIR POLLUTION; ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BCG VACCINATION; CARBON FOOTPRINT; CLINICAL PHARMACOLOGY; COMBINATION CHEMOTHERAPY; CONTACT EXAMINATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENE SEQUENCE; HUMAN; INFECTION RISK; LUNG TUBERCULOSIS; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SOCIAL INTERACTION; SPUTUM CULTURE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84895434826     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00008213     Document Type: Review

References (15)

1. Wood R, Racow K, Bekker LG, et al. Indoor social networks in a South African township: potential contribution of location to tuberculosis transmission. PLoS One 2012; 7: e39246.
2. Andrews JR, Morrow C, Wood R. Modelling the role of public transportation in sustaining tuberculosis transmission in South Africa. Am J Epidemiol 2013; 177: 556-561.
3. Roetzer A, Diel R, Kohl TA, et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med 2013; 10: e1001387.
4. Chigutsa E, Patel K, Denti P, et al. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother 2013; 57: 789-795.
5. Barrios-Payán J, Sagui-Salces M, Jeyanathan M, et al. Extrapulmonary locations of Mycobacterium tuberculosis DNA during latent infection. J Infect Dis 2012; 206: 1194-1205.
6. Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-1473.
7. Ford CB, Shah RR, Maeda MK, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013; 45: 784-790.
8. Dalton T, Cegielski P, Akkslip S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-1417.
9. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
10. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
11. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
12. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
13. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
14. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
15. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021-1028.